• Naar een geintegreerde aanpak van infectieziekten.

      Erkens, C; Spruijt, I; van den Hof, S (2020-07-16)
    • The Nagoya protocol on access to genetic resources and benefit sharing: best practices for users of lactic acid bacteria

      Flach, J; dos Santos Ribeiro, C; van der Waal, MB; van der Waal, RX; Claassen, E; van de Burgwal, LHM (2019-07-15)
    • NAM-supported read-across: From case studies to regulatory guidance in safety assessment.

      Rovida, Costanza; Escher, Sylvia E; Herzler, Matthias; Bennekou, Susanne H; Kamp, Hennicke; Kroese, Dinant E; Maslankiewicz, Lidka; Moné, Martijn J; Patlewicz, Grace; Sipes, Nisha; et al.
    • Nanoethics: Giving orientation to societal reflection

      Brom, FWA; van Est, R; Walhout, B (2022-06-20)
    • Nanomaterial exposures for worker, consumer and the general public

      Kuhlbusch, Thomas A.J.; Wijnhoven, Susan W.P.; Haase, Andrea (2018-04)
    • Nanomaterial grouping: Existing approaches and future recommendations.

      Giusti, A; Atluri, R; Tsekovska, R; Gajewicz, A; Apostolova, MD; Batistelli, CL; Bleeker, EAJ; Oomen, AG; et al. (2020-02-10)
    • Nanomaterials Versus Ambient Ultrafine Particles: An Opportunity to Exchange Toxicology Knowledge.

      Stone, Vicki; Miller, Mark R; Clift, Martin J D; Elder, Alison; Mills, Nicholas L; Møller, Peter; Schins, Roel P F; Vogel, Ulla; Kreyling, Wolfgang G; Alstrup Jensen, Keld; et al. (2017)
      A rich body of literature exists that has demonstrated adverse human health effects following exposure to ambient air particulate matter (PM), and there is strong support for an important role of ultrafine (nanosized) particles. At present, relatively few human health or epidemiology data exist for engineered nanomaterials (NMs) despite clear parallels in their physicochemical properties and biological actions inin vitromodels.
    • Nanomedicinal products: a survey on specific toxicity and side effects.

      Brand, Walter; Noorlander, Cornelle W; Giannakou, Christina; De Jong, Wim H; Kooi, Myrna W; Park, Margriet Vdz; Vandebriel, Rob J; Bosselaers, Irene Em; Scholl, Joep Hg; Geertsma, Robert E (2017)
      Due to their specific properties and pharmacokinetics, nanomedicinal products (NMPs) may present different toxicity and side effects compared to non-nanoformulated, conventional medicines. To facilitate the safety assessment of NMPs, we aimed to gain insight into toxic effects specific for NMPs by systematically analyzing the available toxicity data on approved NMPs in the European Union. In addition, by comparing five sets of products with the same active pharmaceutical ingredient (API) in a conventional formulation versus a nanoformulation, we aimed to identify any side effects specific for the nano aspect of NMPs. The objective was to investigate whether specific toxicity could be related to certain structural types of NMPs and whether a nanoformulation of an API altered the nature of side effects of the product in humans compared to a conventional formulation. The survey of toxicity data did not reveal nanospecific toxicity that could be related to certain types of structures of NMPs, other than those reported previously in relation to accumulation of iron nanoparticles (NPs). However, given the limited data for some of the product groups or toxicological end points in the analysis, conclusions with regard to (a lack of) potential nanomedicine-specific effects need to be considered carefully. Results from the comparison of side effects of five sets of drugs (mainly liposomes and/or cytostatics) confirmed the induction of pseudo-allergic responses associated with specific NMPs in the literature, in addition to the side effects common to both nanoformulations and regular formulations, eg, with liposomal doxorubicin, and possibly liposomal daunorubicin. Based on the available data, immunotoxicological effects of certain NMPs cannot be excluded, and we conclude that this end point requires further attention.
    • Nanoparticle exposure and hazard in the ceramic industry: an overview of potential sources, toxicity and health effects.

      Bessa, Maria João; Brandão, Fátima; Viana, Mar; Gomes, João F; Monfort, Eliseo; Cassee, Flemming R; Fraga, Sónia; Teixeira, João Paulo (2020-05-01)
    • Nanoparticles induce dermal and intestinal innate immune system responses in zebrafish embryos

      Brun, Nadja R.; Koch, Bjørn E. V.; Varela, Mónica; Peijnenburg, Willie J. G. M.; Spaink, Herman P.; Vijver, Martina G.; Institute of Environmental Sciences (CML); Institute of Biology; Institute of Biology; Institute of Environmental Sciences (CML); et al. (2018)
      Metal and plastic nanoparticles elicit innate immune responses in the skin and intestine of zebrafish embryos potentially serving as key event for AOPs.
    • Nanotechnology for a Sustainable Future: Addressing Global Challenges with the International Network4Sustainable Nanotechnology.

      Pokrajac, Lisa; Abbas, Ali; Chrzanowski, Wojciech; Dias, Goretty M; Eggleton, Benjamin J; Maguire, Steven; Maine, Elicia; Malloy, Timothy; Nathwani, Jatin; Nazar, Linda; et al. (2021-12-15)
    • Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines - Multi-country assessment.

      Weibel, Daniel; Sturkenboom, Miriam; Black, Steven; de Ridder, Maria; Dodd, Caitlin; Bonhoeffer, Jan; Vanrolleghem, Ann; van der Maas, Nicoline; Lammers, Gert Jan; Overeem, Sebastiaan; et al. (2018)
      In 2010, a safety signal was detected for narcolepsy following vaccination with Pandemrix, an AS03-adjuvanted monovalent pandemic H1N1 influenza (pH1N1) vaccine. To further assess a possible association and inform policy on future use of adjuvants, we conducted a multi-country study of narcolepsy and adjuvanted pH1N1 vaccines.
    • Nasopharyngeal microbiota profiles in rural Venezuelan children are associated with respiratory and gastrointestinal infections.

      Verhagen, Lilly M; Rivera-Olivero, Ismar A; Clerc, Melanie; Chu, Mei Ling J N; van Engelsdorp Gastelaars, Jody; Kristensen, Maartje I; Berbers, Guy A M; Hermans, Peter W M; de Jonge, Marien I; de Waard, Jacobus H; et al. (2020-01-10)
    • A national FFQ for the Netherlands (the FFQ-NL1.0): development and compatibility with existing Dutch FFQs.

      Eussen, Simone Jpm; van Dongen, Martien Cjm; Wijckmans, Nicole Eg; Meijboom, Saskia; Brants, Henny Am; de Vries, Jeanne Hm; Bueno-de-Mesquita, H Bas; Geelen, Anouk; Sluik, Diewertje; Feskens, Edith Jm; et al. (2018-04-22)
      In the Netherlands, various FFQs have been administered in large cohort studies, which hampers comparison and pooling of dietary data. The present study aimed to describe the development of a standardized Dutch FFQ, FFQ-NL1.0, and assess its compatibility with existing Dutch FFQs.
    • The national FIT-based colorectal cancer screening program in the Netherlands during the COVID-19 pandemic.

      Kortlever, Tim L; de Jonge, Lucie; Wisse, Pieter H A; Seriese, Iris; Otto-Terlouw, Patricia; van Leerdam, Monique E; Spaander, Manon C W; Dekker, Evelien; Lansdorp-Vogelaar, Iris (2021-06-30)
    • National laboratory-based surveillance system for antimicrobial resistance: a successful tool to support the control of antimicrobial resistance in the Netherlands.

      Altorf-van der Kuil, Wieke; Schoffelen, Annelot F; de Greeff, Sabine C; Thijsen, Steven Ft; Alblas, H Jeroen; Notermans, Daan W; Vlek, Anne Lm; van der Sande, Marianne Ab; Leenstra, Tjalling (2017)
      An important cornerstone in the control of antimicrobial resistance (AMR) is a well-designed quantitative system for the surveillance of spread and temporal trends in AMR. Since 2008, the Dutch national AMR surveillance system, based on routine data from medical microbiological laboratories (MMLs), has developed into a successful tool to support the control of AMR in the Netherlands. It provides background information for policy making in public health and healthcare services, supports development of empirical antibiotic therapy guidelines and facilitates in-depth research. In addition, participation of the MMLs in the national AMR surveillance network has contributed to sharing of knowledge and quality improvement. A future improvement will be the implementation of a new semantic standard together with standardised data transfer, which will reduce errors in data handling and enable a more real-time surveillance. Furthermore, the scientific impact and the possibility of detecting outbreaks may be amplified by merging the AMR surveillance database with databases from selected pathogen-based surveillance programmes containing patient data and genotypic typing data.
    • National point prevalence study on carriage of multidrug-resistant microorganisms in Dutch long-term care facilities in 2018.

      van Kleef, Esther; Wielders, Cornelia C H; Schouls, Leo M; Feenstra, Sabiena G; Hertogh, Cees M P M; Bonten, Marc J M; van Weert, Yolanda; Tostmann, Alma; van der Lubben, Mariken; de Greeff, Sabine C (2021-03-10)
    • National prevalence estimates of chlamydia and gonorrhoea in the Netherlands.

      Heijne, Janneke C M; van den Broek, Ingrid V F; Bruisten, Sylvia M; van Bergen, Jan E A; de Graaf, Hanneke; van Benthem, Birgit H B (2018-06-20)
      National prevalence estimates of Chlamydia trachomatis (chlamydia) and Neisseria gonorrhoeae (gonorrhoea) are important for providing insights in the occurrence and control of these STIs. The aim was to obtain national prevalence estimates for chlamydia and gonorrhoea and to investigate risk factors associated with infection.
    • National surveillance pilot study unveils a multicenter, clonal outbreak of VIM-2-producing Pseudomonas aeruginosa ST111 in the Netherlands between 2015 and 2017.

      Pirzadian, Jannette; Persoon, Marjolein C; Severin, Juliëtte A; Klaassen, Corné H W; de Greeff, Sabine C; Mennen, Marcel G; Schoffelen, Annelot F; Wielders, Cornelia C H; Witteveen, Sandra; van Santen-Verheuvel, Marga; et al. (2021-10-25)
      Verona Integron-encoded Metallo-beta-lactamase (VIM) is the most frequently-encountered carbapenemase in the healthcare-related pathogen Pseudomonas aeruginosa. In the Netherlands, a low-endemic country for antibiotic-resistant bacteria, no national surveillance data on the prevalence of carbapenemase-producing P. aeruginosa (CPPA) was available. Therefore, in 2016, a national surveillance pilot study was initiated to investigate the occurrence, molecular epidemiology, genetic characterization, and resistomes of CPPA among P. aeruginosa isolates submitted by medical microbiology laboratories (MMLs) throughout the country. From 1221 isolates included in the study, 124 (10%) produced carbapenemase (CIM-positive); of these, the majority (95, 77%) were positive for the blaVIM gene using PCR. Sequencing was performed on 112 CIM-positive and 56 CIM-negative isolates (n = 168), and genetic clustering revealed that 75/168 (45%) isolates were highly similar. This genetic cluster, designated Group 1, comprised isolates that belonged to high-risk sequence type ST111/serotype O12, had similar resistomes, and all but two carried the blaVIM-2 allele on an identical class 1 integron. Additionally, Group 1 isolates originated from around the country (i.e. seven provinces) and from multiple MMLs. In conclusion, the Netherlands had experienced a nationwide, inter-institutional, clonal outbreak of VIM-2-producing P. aeruginosa for at least three years, which this pilot study was crucial in identifying. A structured, national surveillance program is strongly advised to monitor the spread of Group 1 CPPA, to identify emerging clones/carbapenemase genes, and to detect transmission in and especially between hospitals in order to control current and future outbreaks.